Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Jun 24;27(1):19.
doi: 10.1007/s11906-025-01336-5.

Biomarkers for Predicting Blood Pressure Response to Renal Denervation

Yuyang Ye  1 , Junwen Wang  1 , Yong Peng  2
Affiliations
Review

Biomarkers for Predicting Blood Pressure Response to Renal Denervation

Yuyang Ye et al. Curr Hypertens Rep. .

Abstract

Purpose of review: Since the FDA approved transcatheter renal denervation (RDN) for the treatment of uncontrolled hypertension in 2023, cardiologists have sought to answer a critical question: "Who benefits from RDN?" The blood pressure-lowering effect of RDN varies considerably among individuals, with some showing little to no response. Predicting individual response remains challenging due to the lack of reliable biomarkers. This review summarizes potential biomarkers for predicting the antihypertensive response to RDN, with a focus on their pathophysiological mechanisms.

Recent findings: Biomarkers reflecting renal efferent nerve activity, rather than afferent nerve activity, may serve as more reliable predictors of RDN response. Additionally, biomarkers linked to renin-angiotensin-aldosterone system (RAAS) activation, such as plasma renin activity and miR-133a, have shown promising predictive value. Further research is needed to validate these findings and identify novel biomarkers to optimize patient selection for RDN.

Keywords: Biomarker; Hypertension; Renal denervation; Renin–angiotensin–aldosterone system; Sympathetic nervous system.

PubMed Disclaimer

Conflict of interest statement

Declarations. Competing Interests: The authors declare no competing interests.

Similar articles

See all similar articles

References

    1. Fuchs FD, Whelton PK. High blood pressure and cardiovascular disease. Hypertension. 2020;75(2):285–92. https://doi.org/10.1161/HYPERTENSIONAHA.119.14240 . - DOI - PubMed
    1. Boehme AK, Esenwa C, Elkind MSV. Stroke risk factors, genetics, and prevention. Circ Res. 2017;120(3):472–95. https://doi.org/10.1161/CIRCRESAHA.116.308398 . - DOI - PubMed - PMC
    1. Fowkes FGR, Rudan D, Rudan I, et al. Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010: a systematic review and analysis. Lancet. 2013;382(9901):1329–40. https://doi.org/10.1016/S0140-6736(13)61249-0 . - DOI - PubMed
    1. Bui AL, Horwich TB, Fonarow GC. Epidemiology and risk profile of heart failure. Nat Rev Cardiol. 2011;8(1):30–41. https://doi.org/10.1038/nrcardio.2010.165 . - DOI - PubMed
    1. Chen TK, Knicely DH, Grams ME. Chronic Kidney Disease Diagnosis and Management: A Review. JAMA. 2019;322(13):1294–304. https://doi.org/10.1001/jama.2019.14745 . - DOI - PubMed - PMC

LinkOut - more resources